The stock of Verona Pharma Plc ADR (NASDAQ: VRNA) has increased by 20.65% when compared to last closing price of $86.86.Despite this, the company has seen a gain of 15.82% in its stock price over the last five trading days. zacks.com reported 2025-07-09 that VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
The 36-month beta value for VRNA is at 0.12. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 76.73M, and currently, shorts hold a 10.97% of that float. The average trading volume for VRNA on July 09, 2025 was 1.32M shares.
VRNA’s Market Performance
VRNA’s stock has seen a 15.82% increase for the week, with a 24.25% rise in the past month and a 92.99% gain in the past quarter. The volatility ratio for the week is 5.08%, and the volatility levels for the past 30 days are at 3.83% for Verona Pharma Plc ADR The simple moving average for the past 20 days is 12.71% for VRNA’s stock, with a 84.35% simple moving average for the past 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Wolfe Research repeating the rating for VRNA by listing it as a “Outperform.” The predicted price for VRNA in the upcoming period, according to Wolfe Research is $170 based on the research report published on July 01, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $100. The rating they have provided for VRNA stocks is “Buy” according to the report published on April 28th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to VRNA, setting the target price at $80 in the report published on April 21st of the current year.
VRNA Trading at 28.19% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 5.84% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from Fisher Andrew, who sale 80,000 shares at the price of $11.53 back on Jun 16 ’25. After this action, Fisher Andrew now owns 359,999 shares of Verona Pharma Plc ADR, valued at $922,000 using the latest closing price.
Hahn Mark W, the Chief Financial Officer of Verona Pharma Plc ADR, sale 400,000 shares at $11.40 during a trade that took place back on Jun 11 ’25, which means that Hahn Mark W is holding 12,278,992 shares at $4,560,360 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -1.16 for the present operating margin
- 0.95 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -1.38. The total capital return value is set at -0.29. Equity return is now at value -72.73, with -40.26 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -56.16. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11.7.
Currently, EBITDA for the company is -142.19 million with net debt to EBITDA at 2.27. When we switch over and look at the enterprise to sales, we see a ratio of 71.78. The receivables turnover for the company is 1.91for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.86.
Conclusion
In conclusion, Verona Pharma Plc ADR (VRNA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
